NASDAQ:VICL - Vical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.44 +0.05 (+3.60 %) (As of 09/21/2018 04:00 PM ET)Previous Close$1.44Today's Range$1.36 - $1.4452-Week Range$1.02 - $3.70Volume41,040 shsAverage Volume69,966 shsMarket Capitalization$30.32 millionP/E Ratio-1.43Dividend YieldN/ABeta0.63 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California. Receive VICL News and Ratings via Email Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:VICL CUSIP92560210 Webwww.vical.com Phone858-646-1100 Debt Debt-to-Equity RatioN/A Current Ratio16.89 Quick Ratio16.89 Price-To-Earnings Trailing P/E Ratio-1.43 Forward P/E Ratio-1.52 P/E GrowthN/A Sales & Book Value Annual Sales$13.82 million Price / Sales2.27 Cash FlowN/A Price / CashN/A Book Value$3.42 per share Price / Book0.42 Profitability EPS (Most Recent Fiscal Year)($1.01) Net Income$-12,960,000.00 Net Margins-207.71% Return on Equity-33.70% Return on Assets-28.93% Miscellaneous Employees74 Outstanding Shares21,820,000Market Cap$30.32 million Vical (NASDAQ:VICL) Frequently Asked Questions What is Vical's stock symbol? Vical trades on the NASDAQ under the ticker symbol "VICL." How were Vical's earnings last quarter? Vical Incorporated (NASDAQ:VICL) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The biotechnology company earned $0.74 million during the quarter, compared to the consensus estimate of $0.51 million. Vical had a negative net margin of 207.71% and a negative return on equity of 33.70%. View Vical's Earnings History. When is Vical's next earnings date? Vical is scheduled to release their next quarterly earnings announcement on Monday, October, 22nd 2018. View Earnings Estimates for Vical. What price target have analysts set for VICL? 1 equities research analysts have issued 1 year target prices for Vical's shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Vical's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for Vical. What is the consensus analysts' recommendation for Vical? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vical. Are investors shorting Vical? Vical saw a decrease in short interest in August. As of August 31st, there was short interest totalling 309,897 shares, a decrease of 78.3% from the August 15th total of 1,425,698 shares. Based on an average trading volume of 87,978 shares, the days-to-cover ratio is presently 3.5 days. Currently, 1.6% of the shares of the stock are sold short. View Vical's Current Options Chain. Who are some of Vical's key competitors? Some companies that are related to Vical include Cidara Therapeutics (CDTX), Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Aevi Genomic Medicine (GNMX), Applied Genetic Technologies (AGTC), BioCardia (BCDA), TRACON Pharmaceuticals (TCON), Oncobiologics (ONS), Entera Bio (ENTX), Curis (CRIS), Genocea Biosciences (GNCA), BIONDVAX PHARMA/S (BVXV), Proteon Therapeutics (PRTO), CytRx (CYTR) and Arsanis (ASNS). Who are Vical's key executives? Vical's management team includes the folowing people: Mr. Vijay B. Samant, CEO, Pres & Director (Age 65)Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 51)Dr. Lawrence Russell Smith, Sr. VP of Research (Age 57)Dr. Mammen P. Mammen Jr., Sr. VP of Clinical Devel. (Age 54) Has Vical been receiving favorable news coverage? Media stories about VICL stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vical earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Vical. Who are Vical's major shareholders? Vical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.02%), BlackRock Inc. (1.81%) and Acadian Asset Management LLC (0.82%). Company insiders that own Vical stock include Anthony Alan Ramos, Armistice Capital Master Fund, Armistice Capital, Llc, Lawrence Russell Smith, R Gordon Douglas, Robert C Merton and Vijay B Samant. View Institutional Ownership Trends for Vical. Which major investors are buying Vical stock? VICL stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC and BlackRock Inc.. Company insiders that have bought Vical stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Insider Buying and Selling for Vical. How do I buy shares of Vical? Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vical's stock price today? One share of VICL stock can currently be purchased for approximately $1.44. How big of a company is Vical? Vical has a market capitalization of $30.32 million and generates $13.82 million in revenue each year. The biotechnology company earns $-12,960,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Vical employs 74 workers across the globe. How can I contact Vical? Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at [email protected] MarketBeat Community Rating for Vical (NASDAQ VICL)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 184 (Vote Outperform)Underperform Votes: 129 (Vote Underperform)Total Votes: 313MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: How is an ETF different from a mutual fund?